Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surrogate markers evaluation in pre-demented Alzheimer's disease patients and healthy elderly controls
2011-001756-12Phase 3Completed
- Sponsor
- Cliniques universitaires Saint-Luc
- Start
- Apr 2012
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of flutemetamol in Alzheimer's disease (AD) (2 arms), sponsored by Cliniques universitaires Saint-Luc. Primary endpoint: Primary: Discriminatory power of biomarker combinations. Started Apr 2012; status: completed.
02
Drugs
flutemetamol
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2011-001756-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001756-12.